Core Viewpoint - The article discusses the development of a deep learning-based drug discovery platform called GPS, which utilizes transcriptomic features to identify and optimize compounds for reversing disease-associated transcriptional phenotypes, marking a significant advancement in drug discovery methodologies [3][10][18]. Group 1: Research Background - Current virtual drug screening primarily relies on docking against specific protein targets or AI/ML models trained on screening data, with limited use of transcriptomics, particularly single-cell RNA sequencing, to characterize diseases and cellular states [2]. - The identification of drugs that reverse disease-related transcriptomic features has been explored as a strategy for discovering new uses for existing drugs, but this approach is limited to compounds already in databases and does not support the screening and optimization of novel compounds [2]. Group 2: Research Breakthrough - A research team from Michigan State University and other institutions developed the GPS platform, which screens large compound libraries based on transcriptomic features [3][9]. - The GPS platform predicts the impact of chemical structures on gene expression, allowing for the identification of compounds that can reverse disease-associated gene expression patterns [10][11]. Group 3: Methodology - The GPS platform operates in three key steps: predicting gene expression changes from chemical structures, calculating a "reversal score" to assess the potential of compounds to reverse disease signatures, and optimizing promising compounds using a Monte Carlo tree search algorithm [13][14]. - The research team trained a deep learning model using extensive drug-gene expression data from the LINCS database, enhancing prediction accuracy through a robust collaborative learning framework [11]. Group 4: Applications and Findings - In hepatocellular carcinoma research, the team identified a lead compound with an IC50 value of approximately 4μM against liver cancer cell lines, which was further optimized to achieve sub-micromolar activity [14]. - For idiopathic pulmonary fibrosis (IPF), the team discovered that the existing drug Pyrithyldion could effectively reverse gene expression features associated with IPF, and identified a novel compound, Drug 18, which significantly reduced key fibrosis markers in patient samples [15]. Group 5: Significance - The GPS platform represents a paradigm shift in drug discovery by focusing on disease gene expression features rather than relying solely on known protein targets or limited phenotypic screening data [18]. - This approach allows for the exploration of a vast chemical space and the discovery of novel mechanisms of action, potentially leading to more effective and personalized treatments for diseases like liver cancer and IPF [18].